Announcement
01 Apr 2025
In April 2025, the US Department of Commerce launched a Section 232 investigation into the national security implications of importing pharmaceuticals, pharmaceutical ingredients, and related derivative products. In April 2026, the U.S. Administration concluded the investigation and imposed Section 232 tariffs on patented pharmaceutical imports.
Source
Sign in to access
Number of interventions
9
8 certainly harmful
1 likely harmful
0 liberalising
List of interventions
Implementation date
21 Jan 2029
Revocation date:
No revocation date
Updated: 04 Apr 2026
Import tariff
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As part of this proclamat...
Sign in to see more
Implementation date
29 Sep 2026
Revocation date:
No revocation date
Updated: 04 Apr 2026
FDI: Financial incentive
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The proclamation offers p...
Sign in to see more
Updated: 04 Apr 2026
Local operations incentive
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As a condition for receiv...
Sign in to see more
Updated: 04 Apr 2026
Tax or social insurance relief
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As part of this proclamat...
Sign in to see more
Updated: 04 Apr 2026
Import tariff
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The measure sets a prefer...
Sign in to see more
Updated: 04 Apr 2026
Import tariff
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The measure sets a prefer...
Sign in to see more
Updated: 04 Apr 2026
Import tariff
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients, including active pharmace...
Sign in to see more
Implementation date
29 Sep 2026
Revocation date:
02 Apr 2030
Updated: 04 Apr 2026
Import tariff
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The measure sets an ad va...
Sign in to see more
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 04 Apr 2026
Import tariff
Recent update from 04 Apr 2026:
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As part of this proclamat...
Sign in to see more
Related State Acts
23 Apr 2026
United States of America: Agreement with Regeneron on Most-Favoured-Nation drug pricing and tariff exemption
12 Jan 2026
United States of America: Agreement with AbbVie on Most-Favoured-Nation drug pricing and tariff exemption
08 Jan 2026
United States of America: Agreement with Johnson & Johnson on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Amgen on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Boehringer Ingelheim on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Bristol Myers Squibb on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Genentech on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Gilead on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with GSK on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Merck on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Novartis on Most-Favoured-Nation drug pricing and tariff exemption
19 Dec 2025
United States of America: Agreement with Sanofi on Most-Favoured-Nation drug pricing and tariff exemption
01 Dec 2025
United States of America: U.S. Administration’s commitments under an agreement on pharmaceutical pricing with the United Kingdom
01 Dec 2025
United Kingdom: UK Government’s commitments under an agreement on pharmaceuticals with the United States
06 Nov 2025
United States of America: Agreement with Eli Lilly on Most-Favoured-Nation drug pricing and tariff exemption
06 Nov 2025
United States of America: Agreement with Novo Nordisk on Most-Favoured-Nation drug pricing and tariff exemption
16 Oct 2025
United States of America: Agreement with EMD Serono on Most-Favored-Nation drug pricing and tariff exemption
10 Oct 2025
United States of America: U.S. Administration announces deal with AstraZeneca for Most-Favoured-Nation drug pricing and temporary tariff exemptions
30 Sep 2025
United States of America: Agreement with Pfizer on most-favored-nation drug pricing and tariff exemption
28 Jul 2025
United States of America: US Administration’s commitments under the "U.S.–EU Cooperation Agreement on Reciprocal, Fair and Balanced Trade"
12 May 2025
United States of America: U.S. Administration issues Executive Order to implement Most-Favoured-Nation prescription drug pricing
22 Apr 2025
United States of America: Commerce Department concludes the Section 232 investigation into national security risks of truck imports
15 Apr 2025
United States of America: U.S. Administration concludes Section 232 investigation on imports of processed critical minerals and derivative products
01 Mar 2025
United States of America: U.S. Administration announces additional duties on the imports of timber, lumber and their derivative products to address national security concerns
25 Feb 2025
United States of America: U.S. Administration announces 50% tariffs on copper products and its derivatives to address national security concerns
Threads
See all
This state act is not part of any Thread yet.